Skip to main content
SpringerLink
Log in

When a single pivotal trial should not be enough–the case of drotrecogin-alfa (activated)

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mackenzie AF (2005) Activated protein C: do more survive? Intensive Care Med 31:1624--1626

    Article  PubMed  Google Scholar 

  2. Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C (2005) Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit Care Med 33:2426--2428

    Article  PubMed  Google Scholar 

  3. Wiedermann CJ, Kaneider NC (2005) A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med 5:7

    Article  PubMed  Google Scholar 

  4. Friedrich JO (2006) Drotrecogin alfa (activated) in severe sepsis. N Engl J Med 354:94--95

    Article  PubMed  CAS  Google Scholar 

  5. Anonymous (2005) An unhealthy practice. Nature 437:1065--1066

    Google Scholar 

  6. Taylor R, Giles J (2005) Cash interests taint drug advice. Nature 437:1070--1071

    Article  PubMed  CAS  Google Scholar 

  7. Wiedermann CJ (2005) Bioethics, the Surviving Sepsis Campaign, and the industry. Wien Klin Wochenschr 117:442--444

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Central Hospital of Bolzano, L. Bohler Street 5, 39100, Bolzano, Italy

    Christian J. Wiedermann

Authors
  1. Christian J. Wiedermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian J. Wiedermann.

Additional information

This comment refers to the contribution available at: http://dx.doi.org/10.1007/s00134-006-0090-0

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiedermann, C.J. When a single pivotal trial should not be enough–the case of drotrecogin-alfa (activated). Intensive Care Med 32, 604 (2006). https://doi.org/10.1007/s00134-006-0086-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-006-0086-9

Keywords

Search

Navigation